Understanding Heroin Overdose: A Study of the Acute Respiratory Depressant Effects of Injected Pharmaceutical Heroin.
Opioids are respiratory depressants and heroin/opioid overdose is a major contributor to the excess mortality of heroin addicts. The individual and situational variability of respiratory depression caused by intravenous heroin is poorly understood. This study used advanced respiratory monitoring to follow the time course and severity of acute opioid-induced respiratory depression. 10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes. The main outcome measures were pulse oximetry (SpO2%), end-tidal CO2% (ETCO2%) and neural respiratory drive (NRD) (quantified using parasternal intercostal muscle electromyography). Significant respiratory depression was defined as absence of inspiratory airflow >10s, SpO2% < 90% for >10s and ETCO2% per breath >6.5%. Increases in ETCO2% indicated significant respiratory depression following IOT in 8/10 patients at 30 minutes. In contrast, SpO2% indicated significant respiratory depression in only 4/10 patients, with small absolute changes in SpO2% at 30 minutes. A decline in NRD from baseline to 30 minutes post IOT was also observed, but was not statistically significant. Baseline NRD and opioid-induced drop in SpO2% were inversely related. We conclude that significant acute respiratory depression is commonly induced by opioid drugs prescribed to treat opioid addiction. Hypoventilation is reliably detected by capnography, but not by SpO2% alone. Chronic suppression of NRD in the presence of underlying lung disease may be a risk factor for acute opioid-induced respiratory depression.
Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King's College London, King's Health Partners, Denmark Hill, London, United Kingdom.
Caroline J
CJ
Jolley
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, King's Health Partners, Denmark Hill, London, United Kingdom; Addictions Services, South London & Maudsley NHS Foundation Trust, King's Health Partners, Denmark Hill, London, United Kingdom.
James
J
Bell
Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King's College London, King's Health Partners, Denmark Hill, London, United Kingdom.
Gerrard F
GF
Rafferty
Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King's College London, King's Health Partners, Denmark Hill, London, United Kingdom.
John
J
Moxham
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, King's Health Partners, Denmark Hill, London, United Kingdom; Addictions Services, South London & Maudsley NHS Foundation Trust, King's Health Partners, Denmark Hill, London, United Kingdom.
John
J
Strang
D000284:Administration, Oral; D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects*; D019296:Capnography; D062787:Drug Overdose / Q000175:diagnosis* / Q000503:physiopathology / Q000517:prevention & control; D004576:Electromyography; D005260:Female; D003932:Heroin / Q000009:adverse effects*; D006556:Heroin Dependence / Q000503:physiopathology / Q000534:rehabilitation; D006801:Humans; D007040:Hypoventilation / Q000175:diagnosis* / Q000503:physiopathology / Q000517:prevention & control; D007273:Injections, Intramuscular; D008297:Male; D008691:Methadone / Q000009:adverse effects*; D008875:Middle Aged; D009020:Morphine / Q000009:adverse effects*; D010092:Oximetry; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control
D000701:Analgesics, Opioid; D003932:Heroin; D009020:Morphine; D008691:Methadone